Drugs / Abetimus
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00390091 | Sep 2006 → ? | systemic lupus erythematosus | La Jolla Pharmaceutical Company | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00035308 | ? → Dec 2002 | immunodeficiency disease, lupus nephritis, systemic lupus erythematosus | La Jolla Pharmaceutical Company | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00089804 Comparator | Oct 2004 → Feb 2009 | lupus nephritis, systemic lupus erythematosus | La Jolla Pharmaceutical Company | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | abetimus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00390091 ↗ |
| Known as | abetimus sodium | “LJP 394 (abetimus sodium) is a unique drug that is specifically designed to lower production of antibodies to double-stranded DNA.” NCT00035308 ↗ |
| Known as | LJP 394 | “LJP 394 (abetimus sodium) is a unique drug that is specifically designed to lower production of antibodies to double-stranded DNA.” NCT00035308 ↗ |
| Action | Inhibit | “specifically designed to lower production of antibodies to double-stranded DNA” NCT00035308 ↗ |
| Route | Intravenous | “administered i.v. (in the vien)” NCT00089804 ↗ |